Vaccine may cure chronic myeloid leukemia CML
Johns Hopkins researchers say vaccine appears to ‘mop up’ leukemia cells Gleevec leaves behind — Team cautions that results are very preliminary and they cannot yet rule out other reasons for success – Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).